MedTrace Logo

Amiloride Clinical Trial In Optic Neuritis

NCT01802489 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2018-05-17

No results posted yet for this study

Summary

Optic neuritis (ON) is a common event in Multiple Sclerosis (MS), and causes significant loss of nerve cells in the eye, resulting in poor vision. Optic neuritis also provides a sensitive way of testing the effectiveness of drugs that may help protect from loss of nerve cells in ON and therefore in MS.

The investigators have identified through laboratory and early clinical research in humans that amiloride (a water tablet already in use) may be a drug that can be of benefit in optic neuritis by protecting from loss of nerves cells, ie a neuroprotective drug.

The purpose of this study is to assess the efficacy of amiloride as a neuroprotective drug in optic neuritis

Conditions

Interventions

DRUG

Amiloride

DRUG

Placebo

Placebo capsule identical in appearance to Amiloride 10mg capsule

Sponsors & Collaborators

  • Multiple Sclerosis Society of Great Britain and Northern Ireland

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Principal Investigators

  • Matthew Craner, MBChB PhD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01802489 on ClinicalTrials.gov